These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33048041)

  • 21. Addition of maraviroc to antiretroviral therapy decreased interferon-γ mRNA in the CD4+ T cells of patients with suboptimal CD4+ T-cell recovery.
    Minami R; Takahama S; Kaku Y; Yamamoto M
    J Infect Chemother; 2017 Jan; 23(1):29-34. PubMed ID: 27729193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maraviroc intensification in patients with suppressed HIV viremia has limited effects on CD4+ T cell recovery and gene expression.
    Beliakova-Bethell N; Jain S; Woelk CH; Witt MD; Sun X; Lada SM; Spina CA; Goicoechea M; Rought SE; Haubrich R; Dubé MP
    Antiviral Res; 2014 Jul; 107():42-9. PubMed ID: 24769244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors.
    Banga R; Procopio FA; Cavassini M; Perreau M
    J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway.
    Chandra PK; Gerlach SL; Wu C; Khurana N; Swientoniewski LT; Abdel-Mageed AB; Li J; Braun SE; Mondal D
    Sci Rep; 2018 Oct; 8(1):14702. PubMed ID: 30279437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thalidomide as a Potential HIV Latency Reversal Agent: Is It the Right Time to Forget the Ancestral Sins?
    Vignesh R; Shankar EM
    EBioMedicine; 2017 Oct; 24():20-21. PubMed ID: 28865747
    [No Abstract]   [Full Text] [Related]  

  • 27. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat.
    Maxwell JW; Falcinelli SD; Nefedov A; Dorfmeier C; Wu G; Dewey M; Webber AL; Archin NM; Margolis DM; Hazuda DJ; Barnard RJO; Howell BJ
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
    Parker ZF; Iyer SS; Wilen CB; Parrish NF; Chikere KC; Lee FH; Didigu CA; Berro R; Klasse PJ; Lee B; Moore JP; Shaw GM; Hahn BH; Doms RW
    J Virol; 2013 Mar; 87(5):2401-11. PubMed ID: 23269796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
    De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
    Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.
    Matsuda K; Kobayakawa T; Tsuchiya K; Hattori SI; Nomura W; Gatanaga H; Yoshimura K; Oka S; Endo Y; Tamamura H; Mitsuya H; Maeda K
    J Biol Chem; 2019 Jan; 294(1):116-129. PubMed ID: 30413535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells.
    Li C; Wang HB; Kuang WD; Ren XX; Song ST; Zhu HZ; Li Q; Xu LR; Guo HJ; Wu L; Wang JH
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795436
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
    Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up.
    Ripa M; Pogliaghi M; Chiappetta S; Nozza S; Soria A; Coppalini G; Rovelli C; Tambussi G
    J Clin Virol; 2016 Dec; 85():86-89. PubMed ID: 27865174
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cells potently purge latent HIV-1 beyond TCR-stimulation, activating the PI3K-Akt-mTOR pathway.
    van Montfort T; van der Sluis R; Darcis G; Beaty D; Groen K; Pasternak AO; Pollakis G; Vink M; Westerhout EM; Hamdi M; Bakker M; van der Putten B; Jurriaans S; Prins JH; Jeeninga R; Thomas AAM; Speijer D; Berkhout B
    EBioMedicine; 2019 Apr; 42():97-108. PubMed ID: 30824386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.
    Bobardt M; Kuo J; Chatterji U; Chanda S; Little SJ; Wiedemann N; Vuagniaux G; Gallay PA
    PLoS One; 2019; 14(2):e0211746. PubMed ID: 30716099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.